Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

Joshua F Zeidner, MD, Hanna Knaus, MD, Amer M. Zeidan, MBBS, MHS, Amanda Blackford, Raul Montiel-Esparza, MD, Gabrielle T. Prince, MD, Lukasz P. Gondek, MD PhD, Gabriel Ghiaur, MD PhD, Margaret M. Showel, MD, Amy E. DeZern, MD, Keith W. Pratz, MD, B. Douglas Smith, MD, Mark J. Levis, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Howard Streicher, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2018) 132 (Supplement 1): 335.

https://doi.org/10.1182/blood-2018-99-114961

Published: 2018

Journal Articles

Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer

Mary Philip, MD PhD, Lauren Fairchild, Liping Sun, PhD, Agnes Viale, PhD, Taha Merghoub, PhD, Jedd D. Wolchok, MD PhD, Christina S. Leslie, PhD, Andrea Schietinger, PhD

Blood (2016) 128 (22): 861.

https://doi.org/10.1182/blood.V128.22.861.861

Published: 2016

Journal Articles

Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2016) 128 (22): 2820.

https://doi.org/10.1182/blood.V128.22.2820.2820

Published: 2016

Journal Articles

Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Raúl Montiel-Esparza, MD, Hanna A. Knaus, MD, Joshua F. Zeidner, MD, Ante Vulic, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Mark J. Levis, MD PhD, Howard Streicher, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2015) 126 (23): 1351.

https://doi.org/10.1182/blood.V126.23.1351.1351

Published: 2015

Journal Articles

Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

Blood (2015) 126 (23): 329.

https://doi.org/10.1182/blood.V126.23.329.329

Published: 2015

Journal Articles

EBF Deficient Hematopoietic Progenitor Cells Potentialy Differentiated into Immature B Cell: EBF1 Dispensable for B Cell Linage Commitment from Pro-B to Pre-B Stage

Bidisha Chanda, MBBS,PhD, Tomokatsu Ikawa, PhD, Kazuki Okuyama, PhD, Katsuto Hozumi, PhD, Kiyoshi Ando, MDPhD, Arinobu Tojo, MDPhD, Hiroshi Kawamoto, MDPhD, Ai Kotani, MDPhD

Blood (2014) 124 (21): 5127.

https://doi.org/10.1182/blood.V124.21.5127.5127

Published: 2014

Journal Articles

Histone Acetylation Mediated by Brd1 Is Crucial for Cd8 Gene Activation during Early Thymocyte Development

Yuta Mishima, PhD, Changshan Wang, PhD, Satoru Miyagi, PhD, Atsunori Saraya, MS, Hiroyuki Hosokawa, PhD, Naoto Yamaguchi, PhD, Toshinori Nakayama, MD PhD, Haruhiko Koseki, MD PhD, Ichiro Taniuchi, MD PhD, Atsushi Iwama, MD PhD

Blood (2014) 124 (21): 1576.

https://doi.org/10.1182/blood.V124.21.1576.1576

Published: 2014

Journal Articles

Myeloablative Timed Sequential Busulfan Is Safe in Older Patients

Blood (2014) 124 (21): 3859.

https://doi.org/10.1182/blood.V124.21.3859.3859

Published: 2014

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

Journal Articles

A Single Micro-RNA Can Completely Rescue B-Cell Differentiation Arrest Due To EBF1 Deficiency: Can Micro-RNA Control Cell Fate As a Potential Alternative Of Transcriptional Factor?

Bidisha Chanda, MBBS, PhD, Jun Ogata, MSc, Tomokatsu Ikawa, Ph.D., Kazuki Okuyama, PhD, Kiyoshi Ando, MD, PhD, Arinobu Tojo, MD, PhD, Ai Kotani, MD, PhD

Blood (2013) 122 (21): 338.

https://doi.org/10.1182/blood.V122.21.338.338

Published: 2013

Journal Articles

Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells

Chirag Acharya, Mike Y Zhong, B.S., Daniel Tannenbaum, B.S., Michelle Chen, Matt Ma, Jack Singer, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Yu-Tzu Tai, PhD

Blood (2012) 120 (21): 1847.

https://doi.org/10.1182/blood.V120.21.1847.1847

Published: 2012

Journal Articles

Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer ® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization

Dirk Zboralski, PhD, Julia Hoellenriegel, Christian Maasch, PhD, Anna Kruschinski, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 318.

https://doi.org/10.1182/blood.V120.21.318.318

Published: 2012

Journal Articles

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, MD, Jonathan M. Gerber, MD, Amanda Blackford, Mark Litzow, MD, Matthew C. Foster, MD, Lawrence E. Morris, Jr., MD, Ivana Gojo, MD, Jeffrey E. Lancet, MD, Prithviraj Bose, MD, Raoul Tibes, MD, Stephen A. Strickland, MD, MSCI, Jacqueline M Greer, RN, Michelle Drye, Kevin Meads, Austin Doyle, MD, Richard F Little, MD, MPH, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 47.

https://doi.org/10.1182/blood.V120.21.47.47

Published: 2012

Journal Articles

Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Anna Paola Iori, Karen Brown, David J. Araten, Emilia Scalzulli, Giovanni Fernando Torelli, Maria Stefania De Propris, Corrado Girmenia, Filippo Maria Salvatori, Orly Zelig, Robin Foa, MD, Lucio Luzzatto

Blood (2012) 120 (21): 4408.

https://doi.org/10.1182/blood.V120.21.4408.4408

Published: 2012

Journal Articles

The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,

Julia Hoellenriegel, Dirk Zboralski, PhD, Zeev Estrov, William G. Wierda, MD, PhD, Michael Keating, MD, Anna Kruschinski, PhD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 3878.

https://doi.org/10.1182/blood.V118.21.3878.3878

Published: 2011

Journal Articles

Invasive Fungal Infections in Adults with Newly Diagnosed AML Undergoing Intensive Chemotherapy: Characterization, Risk Factors, and Outcomes in a Single Institution

Kit Lu, MD, Dionissios Neofytos, M.D., Amanda Blackford, Amy Seung, Judith E. Karp, MD

Blood (2011) 118 (21): 4254.

https://doi.org/10.1182/blood.V118.21.4254.4254

Published: 2011

Journal Articles

Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors

Mariela Sivina, PhD, Robert J. Kreitman, MD, Amnon Peled, PhD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 1760.

https://doi.org/10.1182/blood.V118.21.1760.1760

Published: 2011

Journal Articles

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

Christopher G. Kanakry, Allan D. Hess, Christopher D. Gocke, Christopher Thoburn, Ferdynand Kos, Christian Meyer, Janet Briel, Leo Luznik, B. Douglas Smith, Hyam Levitsky, Judith E. Karp

Blood (2011) 117 (2): 608–617.

https://doi.org/10.1182/blood-2010-04-277939

Published: 2011

Journal Articles

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Judith E. Karp, MD, John M. Pagel, MD, PhD, B. Douglas Smith, MD, Jacqueline M Greer, RN, D. Michelle Drye, RN, Kelly M. Smith, MD, Kathleen Dorcy, RN, John J Wright, MD, PhD, L. Austin Doyle, MD, PhD, Elizabeth Garrett-Mayer, PhD, Elihu H. Estey, MD

Blood (2010) 116 (21): 186.

https://doi.org/10.1182/blood.V116.21.186.186

Published: 2010

Journal Articles

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Amy E. DeZern, MD, Anthony Sung, MD, Sharon Kim, MD, Hua-Ling Tsai, MS, Jeanne Kowalski, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Steven D. Gore, M.D., Ephraim Fuchs, MD, Michael A McDevitt, MD, PhD, Leo Luznik, MD, Richard J. Jones, MD, Mark J. Levis, MD, PhD

Blood (2010) 116 (21): 2172.

https://doi.org/10.1182/blood.V116.21.2172.2172

Published: 2010

NARROW

Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer

Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

EBF Deficient Hematopoietic Progenitor Cells Potentialy Differentiated into Immature B Cell: EBF1 Dispensable for B Cell Linage Commitment from Pro-B to Pre-B Stage

Histone Acetylation Mediated by Brd1 Is Crucial for Cd8 Gene Activation during Early Thymocyte Development

Myeloablative Timed Sequential Busulfan Is Safe in Older Patients

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

A Single Micro-RNA Can Completely Rescue B-Cell Differentiation Arrest Due To EBF1 Deficiency: Can Micro-RNA Control Cell Fate As a Potential Alternative Of Transcriptional Factor?

Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells

Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer ® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)

The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,

Invasive Fungal Infections in Adults with Newly Diagnosed AML Undergoing Intensive Chemotherapy: Characterization, Risk Factors, and Outcomes in a Single Institution

Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only